Nova EYE Medical Ltd (eye) Logo

Nova EYE Medical Ltd (EYE)

___:___ · AUD

EYE Chart

EYE's Principal Activity is the manufacture, service and distribution of medical equipment and devices to diagnose and treat eye disease.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) -12.61%
vs ASX 200 (1yr) -26.09%


Market Capitalisation
ASX Rank 1,355 of 2,295
Sector Rank 118 of 177

Key Information

Shares Issued
Sector Healthcare
Similar Companies BIT / THC / AHC
EPS $0.256
DPS $0.135
NTA per share $0.18

Broker Consensus

EYE is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Company Overview

Nova Eye Medical Limited (EYE, formerly Ellex Medical Lasers Limited) is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices to diagnose and treat eye disease. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

Incorporation Details

Incorporated in SA on 11/05/1970 as Nartanda Pty Ltd. Name changed to Cowell Jade Pty Ltd on 22/07/1976. Converted to a public company on 16/12/1986. Name changed to Gemstone Corporation of Australia Ltd (GEC) on 04/01/1987; Ellex Medical Lasers Limited (ELX) on 31/07/2001.

Corporate Details

Head Office Kent Town SA 5067
Registry Computershare
Auditor PricewaterhouseCoopers
Date Listed 12 Sep 1994

Upcoming Calendar (Forecasted)

Date Event
27/08/2021 Report (Prelim)
27/08/2021 Report (Annual)
30/08/2021 Report (Prelim)
24/02/2022 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
21/07/2020 $0.135 100% $0.1929 Interim 29/07/2020

See Upcoming Dividends for all ASX companies.

Key Data
DPS(TTM) $0.135
Gross DPS(TTM) $0.1929
Dividend yield
Gross yield
Payout Ratio --
DRP Features -

Directors & Management

Directors & Management

Name Title Since Bio
Mr Thomas (Tom) Anthony Spurling Non-Executive Director Aug 2020 Director Bio icon

Mr Thomas (Tom) Anthony Spurling

Non-Executive Director

Mr Spurling previously served as the Chief Executive Officer of Ellex Medical Lasers from 2011-2019 and currently acts as a consultant to Nova Eye Medical. Tom has close to 30 years of senior executive experience serving in a range of roles.

Mr Simon Gray Company Secretary Jun 2020
Mr Mike Southard Executive Director Jul 2018 Director Bio icon

Mr Mike Southard

Executive Director

Mr Southard has had spend 26 years with the world's ophthalmology company, Alcon Laboratories of Fort Worth Texas, as Vice President of the Global Surgical business. Prior to this, he was an Executive with Beecham Laboratories (now SmithKline Beecham), and Cooper-Vision, which was acquired by Alcon Laboratories. He is currently part of Ophthalmology, Dermatology and Orthopaedics through his consulting company based in Portland, Oregon, USA. He has experience in both the International and US markets and maintains contacts with opinion leaders in all areas of eye surgery. He has served on Scientific Advisory Boards, Industry Advisory Councils, and also represented the International Markets and the Eye Surgery segment on the team that lead the initial public offering of Alcon in the early 2000's.

Mr Rahmon Coupe Non-Executive Director May 2013 Director Bio icon

Mr Rahmon Coupe

Non-Executive Director

Mr Coupe is Chief Executive Officer and Director of YourAmigo Limited. He has more than 32 years experience in the areas of corporate management, intellectual property management, contract negotiation, business development and engineering and has had work across a range of industries, including information technology and the internet, life sciences and public broadcasting. Mr Coupe has held project and engineering management roles for government research-based organisations, including the Defence Science and Technology Organisation (DSTO). He is a member of the the Risk Committee.

Mr Alexander Sundich Non-Executive Director Jul 2005 Director Bio icon

Mr Alexander Sundich

Non-Executive Director

Mr Sundich is currently a Director of Bridge Street Capital Partners. From 2002 to 2008, he was a senior Executive in the funds management industry. Prior to this, he was an investment banker with Goldman Sachs and CSFB, part of mergers and acquisitions and capital raisings. He is currently the Chairman of Petrel Energy Limited and Cleveland Mining Industry. He is Chairman of the Risk Committee.

Mr Victor Previn Executive Director,Executive Chairman Jul 2001 Director Bio icon

Mr Victor Previn

Executive Director,Executive Chairman

Mr Previn career spans more than 32 years in the laser industry. He has had spend more than 31 years in the ophthalmic laser industry travelling throughout Asia, Europe and the USA in a business development capacity. He is also a Member of the Risk Committee.

Director Transactions

EYE directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
18/09/20 Thomas (Tom) Spurling Buy +20,000 $0.34 $6,800 On-market trade
26/09/18 Mike Southard Buy +20,000 $0.746 $14,910 On-market trade

Director Interests

The current holdings of EYE directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Thomas (Tom) Spurling 18/09/2020 117,992 249,736 N/A N/A
Mike Southard 30/06/2020 N/A 20,000 N/A N/A
Rahmon Coupe 30/06/2020 N/A 914,400 N/A N/A
Alexander Sundich 30/06/2020 N/A 6,300,000 N/A N/A
Victor Previn 30/06/2020 N/A 9,316,031 N/A N/A

Shareholder Info

Top 20 Shareholders About the Data

Data supplied by Morningstar and accurate on Jun 30, 2020.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
National Nominees Limited 21,447,403 14.94%
J P Morgan Nominees Australia Pty Limited 14,198,453 9.89%
Sedico Pty Ltd 8,466,980 5.90%
Bond Street Custodians Limited <Salter D64848 A/C> 6,081,275 4.23%
Ruminator Pty Ltd 5,062,008 3.53%
Pine Street Pty Ltd <Pine Street Super Fund A/C> 3,400,000 2.37%
Canala Super Fund Pty Ltd <Giuseppe Canala S/F A/C> 3,258,173 2.27%
Citicorp Nominees Pty Limited 2,696,375 1.88%
Pine Street Pty Ltd <Pine Street A/C> 1,900,000 1.32%
HSBC Custody Nominees (Australia) Limited Gsco Eca 1,297,617 0.90%
HSBC Custody Nominees (Australia) Limited 1,255,363 0.87%
Neweconomy Com Au Nominees Pty Limited <900 Account> 1,129,066 0.79%
BNP Paribas Nominees Pty Ltd <IB AU Noms Retailclient Drp> 1,052,248 0.73%
Pine Street Pty Ltd <Pine Street A/C> i 1,000,000 0.70%
Five Talents Limited 963,607 0.67%
Mr Douglas Robert Buchanan & Mrs Robyn Lorraine Buchanan <Buchanan Super Fund A/C> 925,000 0.64%
Mr Rahmon Charles Coupe & Mrs Julia Deborah Coupe <Super Fund A/C> 874,400 0.61%
Longridge Partners Pty Ltd 842,725 0.59%
Mr Donald Gerhard Cole 825,800 0.58%
Dr Peter Anthony Stewart 780,000 0.54%

Shareholder Distribution

As reported in the most recent Annual Report.

The most recent Annual Report didn't contain Shareholder Distribution data.

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
National Nominees Limited 30/06/2020 21,447,403 14.94
Sedico Pty Ltd 30/06/2020 8,466,980 5.90
JP Morgan Nominees Australia Limited 30/06/2020 14,198,453 9.89
Natioanl Nominees (Australian Ethical Investment) 28/04/2021 25,193,624 17.53

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
28-04-21 Natioanl Nominees (Australian Ethical Investment) 1,629,400 16.40 17.53
10-12-20 Natioanl Nominees (Australian Ethical Investment) 1,570,312 15.32 16.40
16-09-20 Natioanl Nominees (Australian Ethical Investment) 1,471,211 14.29 15.32
08-09-20 Natioanl Nominees (Australian Ethical Investment) 1,493,526 13.25 14.29
18-08-20 Natioanl Nominees (Australian Ethical Investment) 1,496,848 12.21 13.25

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
No Financial Year End data available
Page Icon
EYE Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.